Innina capitalbymarta g. zanchi·6d agoThe Autonomy LineWho decides how much medicine AI is allowed to practice.
The Womanly Vitals·Oct 29The Double Orphan Designation of Pregnant Women in Clinical ResearchHow pregnant women are Orphans in drug development process, and what regulatory remedies are on horizon.
Julien Dimastromatteo, PhD·Oct 29What a Pre-IND Meeting Can and Cannot DoWhat sponsors can ask FDA before an IND and what the answer does not mean.
Ashish Yadav·Oct 23A Practical Architecture for AI Assisted Medical Legal and Regulatory ReviewMedical, legal, and regulatory review depends on the relationship between a claim and its evidence. A sentence may be accurate in isolation…
Cet·Oct 21Is Thai FDA Registration Really Getting Faster? Four Regulator Voices, Read CarefullyBrands plan launches around “the Thai FDA is slow.” The regulator’s own statements from 2024 to 2026 suggest the picture is changing, with…
Andrew Jonathan Hillman·Oct 20The Biology Is Rarely What Stalls a Biotech’s First FDA Filing. The Chemistry Is.What CBER looks for in a Pre-IND package, and why chemistry, manufacturing and controls deserves more of your prep than the science deck.
Rahuldewangan·Oct 3Why Generative AI Fails Without Source Truth in GxP Regulatory Monitoring*Part 1 of 3 — Source truth before any summary*
TheDispensingMind·Sep 26Mastering Compliance: Bridging Regulatory Theory and Trial Execution#Introduction: Theory Versus Practice in Clinical Trial Management Every clinical research professional learns the same core concepts in…
Yuya Tamai, MD, PhD·Sep 20Patient-Centered Trials in Practice: PRO-CTCAE, CSR Analytics, and FDA GuidanceImplementation, Tolerability Assessment, CSR Outputs, and Trial Design under FDA Guidance 4
Mahtab Shardi·Sep 7MDR Means Three Different Things And Most Professionals Miss OneTry asking three professionals what “MDR” means, and you may get three completely different answers.
